Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction

NCT: NCT02876042 · COMPLETED

NCT IDNCT02876042
StatusCOMPLETED
Start Date2017-03-23
Completion2025-11-03
SponsorCVRx, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension that also have evidence of heart failure with preserved ejection fraction (HFpEF).

Frequently Asked Questions

What is BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction?

BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction is a clinical trial registered under NCT02876042. Current status: COMPLETED.

What is the status of NCT02876042?

The current status of NCT02876042 (BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction) is: COMPLETED.

When did BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction start?

BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction started on 2017-03-23.

Related Devices

PMA P180050Stimulator, carotid sinus nerveCvrx, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑